Caxton Associates »

Y Mabs Therapeutics shares owned by Caxton Associates

Quarter-by-quarter ownership of Y Mabs Therapeutics (YMAB) shares owned by Caxton Associates from 13F filings

Historical chart of Caxton Associates investment in Y Mabs Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Y Mabs Therapeutics held by Caxton Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Y Mabs Therapeutics by Caxton Associates

Quarter filed Position value Share count Share price at filing
2024-03-31 $306k 19k 16.26
2023-03-31 $216k 43k 5.01

More positions owned by Caxton Associates

Tesla Motors Put Option (TSLA)
Citigroup Com New (C)
Amazon (AMZN)
Autoliv (ALV)
Microsoft Corporation (MSFT)
Broadcom (AVGO)
Teck Resources CL B (TECK)
Pioneer Natural Resources (PXD)
salesforce (CRM)
Meta Platforms Cl A (META)
Hess (HES)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Cadence Design Systems (CDNS)
Synopsys (SNPS)

View all positions for Caxton Associates

Top funds holding Y Mabs Therapeutics

BlackRock
Paradigm Biocapital Advisors
Sofinnova Ventures
Vanguard Group
Point72 Asset Management
D. E. Shaw & Co
Pictet Asset Management Holding SA
Geode Capital Management
Acadian Asset Management
Caligan Partners
Soleus Capital Management
Dimensional Fund Advisors
Goldman Sachs Group
Boothbay Fund Management
Northern Trust

View all funds holding Y Mabs Therapeutics